FDA puts Atara’s INDs on hold after rejection; Ascletis' safety data for obesity pill

Plus, news about Amylyx and Sanofi: FDA places hold on Atara Biotherapeutics’ active INDs: The holds affect the T cell therapy that the agency rejected last week as well as another program called ATA3219. According ...